Your session is about to expire
← Back to Search
Latiglutenase for Celiac Disease
Study Summary
This trial is testing a new medication for celiac disease patients who have been following a gluten-free diet for at least a year.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been told by a doctor that you have Type 1 Diabetes.You are allergic to wheat.You have a history of stomach ulcers, esophagus inflammation, irritable bowel syndrome, or inflammatory bowel disease.You have had certain types of stomach surgery that make food move through your stomach too quickly.You have had a long-lasting or recent infection in your stomach or intestines.You have had at least one symptom that you would describe as moderate or worse in the past 28 days.You have active colitis or dermatitis herpetiformis.You have a type of celiac disease that hasn't responded to treatment.You have been diagnosed with Crohn's disease through a biopsy.You have tested positive for a particular virus or infection.You have been on a gluten-free diet for at least 12 months.
- Group 1: Placebo
- Group 2: Latiglutenase
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this clinical trial represent a pioneering endeavor?
"At the time of writing, 2 clinical trials are recruiting participants to study Latiglutenase in two distinct cities across one nation. This investigational drug was initiated by Immunogenics, LLC back in 2019 and initially included 120 volunteers; it has since gone on to complete its Phase 2 Drug Approval stage with a total of 18324 studies completed."
Is the enrollment period for this experiment limited to individuals over 25 years of age?
"This trial is open to all adults aged 18-80. For minors, there are 12 clinical trials available and 24 for those that exceed the cutoff age of 65 years old."
What is the current patient count for this inquiry?
"Affirmative. Clinicaltrials.gov displays that this clinical trial, initially posted on November 1st 2019, is currently recruiting patients. About 120 subjects need to be enrolled from a single medical facility."
Are recruitment efforts still underway for this research endeavor?
"Affirmative. Data hosted on clinicaltrials.gov verifies that this scientific investigation, which was initially posted November 1st 2019, is currently recruiting participants. Approximately 120 patients need to be sourced from a single medical facility."
Has Latiglutenase been granted regulatory acceptance by the FDA?
"Latiglutenase has been deemed a score of 2 on Power's safety scale, since clinical trials have only provided evidence supporting its security rather than efficacy."
Can you shed light on prior experiments related to Latiglutenase?
"Currently, two medical trials investigating the efficacy of Latiglutenase are underway. There is no Phase 3 trial in progress at this time, however there are a couple sites conducting research with the drug located mainly in Palo Alto, California."
What criteria must individuals satisfy to be considered a viable candidate for this experiment?
"Eligibility criteria for this study requires volunteers to have celiac disease and aged between 18-80 years old. The research team aims to enrol a total of 120 participants in the trial."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger